Higher Anthracycline Doses Linked to Breast Malignancy Risk in Childhood Cancer Survivors

Higher doses of anthracyclines are associated with increased risk of breast cancer in women who survived childhood cancer, regardless of whether they have mutations that predispose them to cancer, according to findings based on the St. Jude Lifetime Cohort Study.

Read more: https://www.onclive.com/publications/oncology-live/2019/vol-20-no-13/higher-anthracycline-doses-linked-to-breast-malignancy-risk-in-childhood-cancer-survivors